Burzynski Research Institute (BZYR) Free Cash Flow (2010 - 2025)
Burzynski Research Institute (BZYR) posted Free Cash Flow of -$823106.0 for Q4 2025, down 767.28% sequentially from -$94907.0 in Q3 2025, and up 7.54% YoY from -$765361.4 in Q4 2024.
Burzynski Research Institute (BZYR) Free Cash Flow (2010 - 2025) Analysis & Trends
Burzynski Research Institute has reported Free Cash Flow for 16 years, with the latest figure at -$823106.0 in Q4 2025.
- Quarterly Free Cash Flow rose 7.54% year-over-year to -$823106.0 in Q4 2025, while the trailing twelve-month figure through Nov 2025 was -$257784.0 (up 79.14% YoY) and the FY2025 annual result came in at -$388531.0, up 25.82% from the prior year.
- Free Cash Flow slipped to -$823106.0 in Q4 2025 per BZYR's latest filing, from -$94907.0 in the prior quarter.
- Over five years, Free Cash Flow peaked at $709372.0 in Q1 2025 and troughed at -$890275.0 in Q4 2024.
- A 5-year average of -$125190.2 and a median of -$85921.0 in 2021 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow slumped 342.73% in 2024, then soared 615.46% in 2025.
- Over 5 years, Free Cash Flow stood at -$95155.0 in 2021, then surged by 49.99% to -$47591.0 in 2022, then sank by 322.54% to -$201089.0 in 2023, then slumped by 342.73% to -$890275.0 in 2024, then grew by 7.54% to -$823106.0 in 2025.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$823106.0, -$94907.0, and -$49143.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Burzynski Research Institute | 1.31 Mn | 1.31 Mn | - | -823,106.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | -823,106.00 |
| Nov 30, 2025 | -823,106.00 |
| Aug 31, 2025 | -94,907.00 |
| Aug 31, 2025 | -94,907.00 |
| May 31, 2025 | -49,143.00 |
| May 31, 2025 | -49,143.00 |
| Feb 28, 2025 | 709,372.00 |
| Feb 28, 2025 | 709,372.00 |
| Nov 30, 2024 | -890,275.00 |
| Nov 30, 2024 | -890,275.00 |
| Aug 31, 2024 | -148,098.00 |
| Aug 31, 2024 | -148,098.00 |
| May 31, 2024 | -59,530.00 |
| May 31, 2024 | -59,530.00 |
| Feb 29, 2024 | -137,620.00 |
| Feb 29, 2024 | -137,620.00 |
| Nov 30, 2023 | -201,089.00 |
| Nov 30, 2023 | -201,089.00 |
| Aug 31, 2023 | -119,768.00 |
| Aug 31, 2023 | -119,768.00 |